Ongoing Strategic Negotiations Towards a Licensing Agreement Strong Momentum for CellTolerance: Over 1,500 Procedures Completed, New Centers...
Paris and Boston, May 20, 2025 - 5:45 p.m. CEST - Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
Over 75 physicians attended educational presentations about the breakthrough impact of needle-based Confocal Laser Endomicroscopy and AI on the...
Paris and Boston, April 30, 2025 – 9:15 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
Pancreatic cyst abstracts build on endorsement of Cellvizio® by Europe’s leading endoscopy society, ESGE, as a key tool for improving pancreatic...
Commercial activities remain strong, including CellTolerance® launch Recently approved safeguard proceeding yielding productive creditor and...
The Company also confirms that it is pursuing licensing discussions in other therapeutic areas The protective framework of the safeguard...
The aim of the procedure is to optimize the Company's financial structure in order to adapt it to the needs of its future growth The...
ESGE, Europe’s leading endoscopy society, endorses Cellvizio® as a key tool for improving pancreatic cyst diagnostic accuracy, marking a major step...
Cellvizio was successfully integrated into TransOral Robotic Surgery (TORS) procedures to assess peripheral mucosal margins in the larynx,...
13th U.S. AI patent awarded to Mauna Kea Expanded patent portfolio boosts platform value, supports strategic partnerships Paris and Boston,...
Full Year Sales excluding licenses of €5.6m, down 9% YoY amid delayed capital sales and no revenue from JV in China Two specialized investment banks...
